Behr T, Becker W, Hannappel E, Goldenberg D M, Wolf F
Department of Nuclear Medicine, Friedrich-Alexander-University of Erlangen-Nuremberg, Germany.
Cancer Res. 1995 Dec 1;55(23 Suppl):5777s-5785s.
The aim of this study was to investigate targeting of the liver metastases by directly 99mTc-labeled complete (IgG) and fragmented antibodies [F(ab')2 and Fab'] in relation to their kinetics and metabolic fate. A total of 127 patients with metastatic colorectal cancer were examined [IgG1, BW 431/26 (Behringwerke, Marburg, Germany) n = 50; F(ab')2, F023C5 (Sorin Biomedica, Saluggia, Italy) n = 58; Fab', IMMU-4 (Immunomedics, Morris Plains, NJ) n = 19]. Native monoclonal antibodies (MAbs), serum samples from 10 min to 24 h postinjection (p.i.), and urine were analyzed by gel filtration chromatography. Kinetic data were deduced from whole-body and single-photon emission computed tomographic scans, performed 10 min to 24 h p.i. (region-of-interest technique). In BW 431/26, 96% of injected activity was labeled IgG1; in F023C5, 29% was F(ab')2, and 71% was Fab'; and in IMMU-4, 92% was Fab', and 8% was F(ab')2. Serum half-lives were: IgG1, 36 h (liver uptake predominant); F(ab')2, 16 h; and Fab', 4 h (renal uptake predominant). All MAbs were metabolized, fragments more rapidly than IgG, to low-molecular-weight products and excreted into the urine (e.g., Tc-cystine). In targeting liver metastases, sensitivities were found to be higher for fragments (44.1, 72.5, and 80% for BW 431/26, F023C5, and IMMU-4, respectively) but at significantly lower tumor:background ratios than with IgG (1.78 +/- 0.29 versus 1.29 +/- 0.11 and 1.43 +/- 0.53; P < 0.01). With IgG, there was a continuous tumor uptake over 24 h, whereas with fragments, the maximal uptake occurred mostly within 1 h, with subsequent clearance being slower for antigen-bound activity than for nonspecific background. Hence, diagnosis was possible mostly after 4 h with fragments but often not before 24 h with IgG. These results show that the higher sensitivity of fragments in liver lesion targeting at earlier p.i. times does not rely on an increased antibody uptake but on a more rapid clearance of nonspecific background activity due to faster metabolism and excretion. Intact MAbs show a slow, continuous uptake, leading to higher tumor:background ratios at later p.i. times, often beyond the imaging possibilities of 99mTc.
本研究的目的是研究直接用99mTc标记的完整(IgG)抗体和片段化抗体[F(ab')2和Fab']对肝转移灶的靶向作用及其动力学和代谢转归。共检查了127例转移性结直肠癌患者[IgG1,BW 431/26(德国马尔堡贝林werke公司)n = 50;F(ab')2,F023C5(意大利萨卢贾索林生物医学公司)n = 58;Fab',IMMU - 4(美国新泽西州莫里斯平原免疫医学公司)n = 19]。通过凝胶过滤色谱法分析天然单克隆抗体(MAbs)、注射后10分钟至24小时的血清样本以及尿液。动力学数据由注射后10分钟至24小时进行的全身和单光子发射计算机断层扫描推导得出(感兴趣区技术)。在BW 431/26中,96%的注射活性为标记的IgG1;在F023C5中,29%为F(ab')2,71%为Fab';在IMMU - 4中,92%为Fab',8%为F(ab')2。血清半衰期分别为:IgG1,36小时(以肝脏摄取为主);F(ab')2,16小时;Fab',4小时(以肾脏摄取为主)。所有单克隆抗体均发生代谢,片段比IgG代谢更快,生成低分子量产物并排泄到尿液中(例如,锝 - 胱氨酸)。在靶向肝转移灶方面,发现片段的敏感性更高(BW 431/26、F023C5和IMMU - 4分别为44.1%、72.5%和80%),但肿瘤与背景的比值明显低于IgG(1.78±0.29对1.29±0.11和1.43±0.53;P<0.01)。使用IgG时,24小时内肿瘤持续摄取,而使用片段时,最大摄取大多发生在1小时内,随后与抗原结合的活性清除比非特异性背景慢。因此,使用片段时大多在4小时后可进行诊断,而使用IgG时通常在24小时前无法诊断。这些结果表明,片段在注射早期对肝病变靶向的较高敏感性并非依赖于抗体摄取增加,而是依赖于由于代谢和排泄更快导致非特异性背景活性清除更快。完整单克隆抗体显示出缓慢、持续的摄取,导致注射后期肿瘤与背景的比值更高,这常常超出了99mTc的成像可能性。